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in relation to stroke or systemic embolism and mean rank 1.15 for major bleeding. 
Edoxaban (60mg od) was also highly ranked (means 3.24 and 1.92, respectively). We 
did not see strong evidence that NOACs have advantages over LMWH in primary 
prevention, or over warfarin in acute treatment and secondary prevention of VTE, but 
risk of bleeding complications was lower for some NOACs than for warfarin. In sen-
sitivity analyses, key decisions we made in the process did not materially affect the 
results. ConClusions: NOACs have advantages over warfarin for stroke prevention 
in AF and acute treatment of VTE, but we found no evidence that they should replace 
the standard treatments for primary and secondary prevention of VTE.
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objeCtives: To describe the rate of unplanned admissions in patients with multi-
morbidity and calculate the percent of patients with at least one unplanned admis-
sion by risk classification based on the results of a predictive model Methods: 
Cross-sectional study. In September 2013 all Basque Country citizens were classified 
in risk groups based on a prediction model that used data from a 2 year period: 
age, sex, diagnoses, procedures, prescriptions and costs from the first year as the 
explanatory variables and healthcare cost in the second year as the dependent 
one. A Patient with multimorbidity was defined as following: 2 or 3 from diabetes, 
chronic obstruction pulmonary disease and chronic heart failure; or multimorbid-
ity definition used by Ollero et al published elsewhere. People younger than 14 or 
with a diagnosis of cancer, a transplant or dialysis were excluded. Multimorbidity 
was classified in three risk groups based on the expected healthcare cost percen-
tiles (< 75; 75-95; > 95). Case-mix Adjusted Clinical Groups (ACG) was used for both 
prediction and definition of multimorbidity. Rate of unplanned admissions and the 
probability of one or more unplanned admissions by risk group during the follow-
ing year to their classification were calculated Results: A total of 24,247 people 
met the criteria of multimorbidity (61.3%males) with a mean age of 75.5 years. 
2,795 were classified as low-risk, 10,598 as medium-risk and 10,853 as high-risk. 
The rate of unplanned admissions was 148.4/1000 in the low-risk group, 340.3/1000 
in the medium-risk group and 861.6/1000 in the high-risk group (Mantel-Haenszel 
trend test p< 0,001). 11.4%, 22.8% and 44.6% of the patients in each risk group 
required one or more unplanned admissions during the following year, respectively 
(p< 0,001) ConClusions: Predictive risk models, based on ACG, allow classifying 
patients with multimorbidity in risk groups. This makes possible a better develop-
ment of personalized, cost-efficient and patient-centered care plans
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objeCtives: Update epidemiology and estimate Chronic Heart Failure (CHF) related 
costs in general practice setting Methods: We used Health Search, an Italian gen-
eral practice database formed by about 1,000 GPs. We collected demographics, clini-
cal informations, drug prescriptions, co-morbidities, and lifestyle measurements, 
reflecting “real world” practice. Results: We analyzed data of 13,633 CHF (mean 
age was 76.78 years) patients that resulted in a prevalence of 1.25%. We observed 
similar prevalence in men and women; prevalence increased significantly with age, 
in both men and women. There were some substantial differences across regions 
(eg.: Emilia Romagna 1.54% vs. Sardinia 0.61%). Incidence rate was slightely lower 
than that reported in the literature (1.99*1000 person-years) with some regional 
diffrences: 3.24*1000 Emilia Romagna as oposed to 1.21*1000 in Puglia and Marche. 
Women had a higher incidence rate than men (2.05*1.000 vs. 1.92*1000). Overall, 
mean cost in a cohort of 7.710 patients (excluding 67,7% of patients that had a null 
cost registrated by phisicians) was 950.22€ /patient/year (DS: 1135,27), while median 
cost was 643,16€ . Age and NYHA class seemed to influence costs for elderly patients, 
while ex-smokers, alcohol abusers and patients with alcohol related diseases had a 
significant reduction of costs. ConClusions: Real world data is needed to under-
stand the epidemiology of and costs due to CHF in primary care. The epidemiology 
of CHF here reported is in line with current literature. Concerning CHF-related costs 
and the respective determinants, this is the first study examining the Italian general 
practice setting. The present analysis gives an important contribution in updating 
epidemiology and estimating CHF-related costs.
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objeCtives: Hypertriglyceridemia (HTG) is a common condition characterized 
by elevated triglyceride (TG) levels with the threshold inconsistently defined but 
often appearing as ≥ 2.26 mmol/L; patients with TG levels ≥ 5.6 mmol/L have severe 
HTG (sHTG). The objective of this study was to evaluate the burden of HTG and 
report unmet needs. Methods: MEDLINE- and Embase-indexed databases were 
systematically searched, pairing keywords for elevated TG levels with outcomes, to 
identify English-language articles published from 1/1/2002–4/14/2014. Conference 
proceedings from the past four years were also reviewed. Studies evaluating clini-
cal, patient-centered, economic, and epidemiologic outcomes in adults with TG 
levels ≥ 2.26 mmol/L were included. Results: Of the 1,225 articles identified, 160 
studies were included. Prevalence of HTG (1.2%–55.8% globally) was reported incon-
sistently. Significant associations were identified between HTG and cardiovascular 
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objeCtives: Pharmacological adherence plays an essential role in controlling hyper-
cholesterolemia. Pharmacological care is also affected by the prescribing inappro-
priateness and adverse drug reactions (ADRs). ADRs can lead to a perceived lack of 
therapy effectiveness and subsequent suboptimal adherence. Our aim was to evaluate 
the impact of statin-induced, muscle-related ADRs on patients’ therapy adherence, 
and how this relationship may compromise the efficacy of physicians’ prescribing 
choices and health outcomes in clinical practice Methods: A retrospective cohort 
study was performed using data from databases of 4 Local Health Units (LHUs) located 
in Emilia-Romagna, Toscana and Umbria regions, with an overall population of about 
1.1 millions of inhabitants. All subjects aged≥ 18 years with a first prescription for 
statins in the period 01/01/2007-30/06/2008 were included. Baseline and follow-up 
LDL-C levels were considered Results: A total of 71,855 patients (51% men, age 
68.6±10.6) were included. Among them, 31,544 (43.9%) had ≥ 1 LDL-C values during 
the follow-up period: only 37.4% of these patients achieved LDL-C target. 23.6% of 
patients underwent ≥ 1 CPK measurement: out of range values were identified in 
37.8% of them. Patients with steadily normal values of CPK showed a better medi-
cation-taking behavior compared to patients whose CPK values were out of normal 
range. Furthermore, a greater percentage of switching to other statin drug and/or 
dosage was observed in patients with out of range CPK levels compared to those with 
normal serum CPK levels ConClusions: Our findings indicate that physiological 
serum CPK levels were associated with greater adherence to statin therapy, sup-
porting a causal link between non-adherence behavior and muscle-related ADRs 
occurrence. Since statin benefits are associated with their chronic use, physicians 
should be aware about the relevance of monitoring their patients for this harmful 
link to prevent unsuitable therapeutic decisions, further decreasing adherence, and 
achieve long-term health outcomes
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objeCtives: This study evaluated the incidence and costs of lead damage within one 
year of pacemaker (PM), implantable cardiac defibrillator (ICD), and cardiac resynchro-
nization therapy defibrillator (CRT-D) device replacement. Methods: Using Truven 
US insurance claims (1/1/2009 – 12/31/2013), we identified patients who underwent 
a CIED generator replacement. We excluded patients with existing lead damage or 
active infection. Data were analyzed for one year prior to and following the replace-
ment procedure, with device replacement the index date for analysis. During follow-
up we considered lead damage to have occurred if there was any recorded visit with a 
procedure code for lead revision or repair and no concurrent code for infection. A Cox 
model, adjusted for baseline demographics and comorbidities, was used to evaluate 
variables associated with risk of lead damage. Results: The study cohort included 
45,250 patients (72±14 years; 64% male), including 22,557 (50%) PMs, 20,632 (46%) 
ICDs, and 2,061 (5%) CRT-Ds. Lead damage was observed in 406 (0.90%) patients. The 
incidence of lead damage was significantly influenced by CIED type (PM: 0.46%; ICD: 
1.27%; CRT: 1.94% p < .001). Similarly, total hospitalization cost associated with lead 
revision / repair was influenced by CIED type (PM: $19,959; ICD: $ 24,885; CRT: $46,229, 
p= 0.048). As compared to PMs, ICDs (HR = 2.14, 95% CI 1.68 – 2.74) and CRTs (HR = 2.97, 
95% CI 1.99 – 4.43) had a significantly higher risk of lead damage. ConClusions: 
This is the first nationally representative study to assess the incidence and associ-
ated costs of lead damage following CIED generator replacement in the US. Patients 
with an ICD or CRT have a significant 1-2% risk of lead damage, which is associated 
with substantial hospitalization-related costs. Strategies are needed at the time of 
generator replacement to minimize inadvertent lead damage.
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objeCtives: To determine the best oral anticoagulant(s) across four medical con-
ditions: stroke prevention in atrial fibrillation (AF), primary prevention of venous 
thromboembolic disease (VTE), acute treatment of VTE, and secondary prevention of 
VTE; using network meta-analysis to compare novel oral anticoagulants (NOACs) with 
warfarin and/or low molecular weight heparin (LMWH). Methods: We undertook 
four systematic reviews and network meta-analyses of randomised controlled trials. 
An extensive search and risk of bias assessment were followed by network meta-anal-
yses within each condition, and additionally we performed combined meta-analyses 
across the four reviews for key safety outcomes. Through consultation between clini-
cians and methodologists, we needed to make various decisions about groupings of 
interventions and doses, and of different endpoints, for analysis. Results: 85 trials 
were included across the reviews, including a mixture of phase III trials and phase 
II dose-ranging trials. For stroke prevention in AF, apixaban (5mg bd) was among the 
best interventions for a range of efficacy and safety outcomes with mean rank 2.35 
